Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — H1 2021 Earnings Presentation
12 slides from Vivoryon Therapeutics's earnings presentation, Sep 21, 2021
Slide 1: Half Year 2020 Results Webcast and Conference Call
HALF YEAR 2020 RESULTS WEBCAST AND CONFERENCE CALL September 21, 2021 |Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics N.V. (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed
Slide 3: Vivoryon Therapeutics Overview
VIVORYON THERAPEUTICS Overview Enzyme inhibition for targeted intervention: Modulating the activity of proteins altered in disease settings Lead product candidate varoglutamstat in AD: Phase 2a evidence of disease-modifying activity Statistically significant improvement in working memory after 3-mon
Slide 4: Key Updates
KEY UPDATES ◆ US Phase 2a/b VIVA-MIND study for varoglutamstat in patients with early AD being initiated as planned, with the first site now approved to initiate screening ◆ Strategic regional licensing partnership with Simcere to develop and commercialize N3pE amyloid- targeting medicines to treat
Slide 5: Therapeutic Interventions in AD
THERAPEUTIC INTERVENTIONS IN AD Varoglutamstat Inhibits Formation of Toxic Abeta Species Upstream of Other Approaches ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS CCL2 Increased activity of glutaminyl cyclase (QPCT) is Abeta upregulated in AD associated with AD patholo
Slide 6: Clinical Development Strategy
CLINICAL DEVELOPMENT STRATEGY Clear Path To Regulatory Approval with Upside Potential for Accelerated Approval Pivotal study or accelerated approval Two possible scenarios Phase 2b VIVIAD Safety, tolerability and efficacy in 250 § Application for accelerated Patients MCI and mild AD approval (based
Slide 7: Phase 2a/b Study - Ongoing
PHASE 2A/B STUDY - ONGOING Efficacy and Safety of Varoglutamstat in Patients With Early AD1 START INTERIM DATA Site visits 4 8 12 16 24 36 48 60 72 2H21 1H23 w 1-24 PHASE 2A FUTILITY/STAGE ADAPTIVE DOSE FINDING GATE TO 2B w 25 – 72 ENDPOINTS 180 patients PHASE 2B Safety/Final Dose Primary efficacy:
Slide 8: Clinical Development Strategy
CLINICAL DEVELOPMENT STRATEGY Clear Path To Regulatory Approval with Upside Potential for Accelerated Approval Pivotal study or accelerated approval Two possible scenarios Phase 2b VIVIAD Safety, tolerability and efficacy in 250 § Application for accelerated Patients MCI and mild AD approval (based
Slide 9: Condensed Statement of Profit and Loss
CONDENSED STATEMENT OF PROFIT AND LOSS In €k Jan – June 2021 Jan – June 2020 % Research and development expenses 9,456 6,380 48 General and administrative expenses 2,337 1,138 >100 Other operating income (5) (38) >100 Operating loss 11,788 7,480 58 Finance result (117) 92 >(100) Loss for period 11,6
Slide 10: Key Financial Figures
KEY FINANCIAL FIGURES In €k June 30, 2021 Dec 31, 2020 Cash and cash equivalents 19,832 26,306 Total assets 23,041 29,751 Total equity 15,471 26,221 Shares (number) 19,975,482 19,975,482 In €k Jan – June 2021 Jan – June 2020 Cash flows used in operating activities (6,540) (6,353) Cash flows used in
Slide 11: Multiple Avenues to Value Generation
MULTIPLE AVENUES TO VALUE GENERATION Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER‘S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL
Slide 12: Q&A
Q&A
Vivoryon Therapeutics — H1 2021 Earnings Presentation on 6ix